Oncotelic's 20nm Nanoparticle Technology Enters Human Trials for Enhanced Breast Cancer Treatment
TL;DR
Oncotelic's 20nm Deciparticle technology provides competitive advantage by achieving full bioavailability of Everolimus, maximizing tumor targeting compared to 10% absorption with oral formulations.
Oncotelic's proprietary 20nm nanoparticle platform works by optimizing particle size for enhanced drug delivery, using intravenous administration to improve tumor targeting and therapeutic efficacy.
This technology makes tomorrow better by improving cancer treatment outcomes through targeted drug delivery that minimizes side effects and enhances patient quality of life.
Oncotelic's 20nm nanoparticles achieve what oral formulations cannot, delivering 100% bioavailability of cancer drugs directly to tumors through precise size optimization.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics Inc. has initiated Phase 1 clinical trials for Sapu003, marking a significant advancement in nanomedicine delivery for breast cancer treatment. The Australian Human Research Ethics Committee approval validates the company's proprietary 20nm nanoparticle technology, which represents a critical breakthrough in targeted drug delivery systems.
The Deciparticle(TM) platform achieves full bioavailability when delivering Everolimus (Afinitor(R)) intravenously, a dramatic improvement over conventional oral formulations that typically achieve only 10% absorption. This enhanced delivery system maximizes tumor targeting and therapeutic efficacy while potentially reducing side effects associated with traditional chemotherapy approaches that expose healthy tissues to cytotoxic agents.
Particle size emerges as the crucial factor in effective anticancer drug delivery. Conventional chemotherapy methods often fail to distinguish between healthy and cancerous tissues, leading to severe side effects that limit treatment options and patient quality of life. Oral targeted therapies frequently struggle to reach tumors at therapeutic concentrations, undermining their potential effectiveness.
Oncotelic's strategic partnership with Medicilon supports up to 20 Investigational New Drug projects, creating a rapid IND platform that significantly shortens development timelines. This accelerated approach enables multiple Deciparticle(TM) drug candidates to reach clinical testing quickly, potentially transforming the pipeline for cancer therapeutics. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
This technological advancement addresses fundamental challenges in oncology treatment by improving drug delivery precision. Enhanced tumor targeting could lead to more effective cancer treatments with reduced systemic toxicity, potentially improving patient outcomes and quality of life during treatment. The full bioavailability achieved with the 20nm nanoparticles represents a substantial improvement over existing delivery methods, offering new possibilities for cancer drug development and patient care.
The convergence of nanotechnology and pharmaceutical development through platforms like Deciparticle(TM) signals a shift toward more precise, targeted cancer therapies. As these technologies advance through clinical trials, they could establish new standards for drug delivery efficiency and therapeutic precision in oncology treatment protocols worldwide.
Curated from InvestorBrandNetwork (IBN)
